<DOC>
	<DOCNO>NCT00269087</DOCNO>
	<brief_summary>This study evaluate safety medicine COPD ( Chronic Obstructive Pulmonary Disease ) . This study last 56 week , subject visit clinic 16 time . Subjects give breathe test , record breathing symptom daily diary card .</brief_summary>
	<brief_title>GW815SF For Chronic Obstructive Pulmonary Disease ( Chronic Bronchitis , Emphysema )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Diagnosis COPD . Exclusion criterion : Diagnosis asthma uncontrolled medical condition respiratory disorder COPD . Other inclusion exclusion criterion evaluate first study visit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>COPD</keyword>
	<keyword>Emphysema</keyword>
</DOC>